Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

References

• Chan CWH, Law BMH, So WKW, et al. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 2020 Jun;146(6):1395–1404.
   PubMed Web of Science ®Google Scholar
• Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
   PubMed Web of Science ®Google Scholar
• WHO: Cancer [Internet]. World Health Organization; 2020 [cited 2020 Oct 02]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Wormann B. Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm. 2017 Feb;40(2):55–64.
   Google Scholar
• Odle TG. Precision medicine in breast cancer. Radiol Technol. 2017 Mar;88(4):401M–421M.
   PubMed Web of Science ®Google Scholar
• Gompel A. [Hormone and breast cancer]. Presse Med. 2019 Oct;48(10):1085–1091.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Dickler MN. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist. 2018 May;23(5):528–539.
   PubMed Web of Science ®Google Scholar
• Del Re M, Michelucci A, Simi P, et al. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev. 2012 Aug;38(5):442–450.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;;365(9472): 1687–1717.
   PubMed Web of Science ®Google Scholar
• Breast International Group 1-98 Collaborative G, Thurlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747–2757.
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45–53.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015 Oct 3;386(10001): 1341–1352.
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7;302(13):1429–1436.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Sangkuhl K, Guchelaar HJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018 May;103(5):770–777.
   PubMed Web of Science ®Google Scholar
• Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep. 1980 Jun-Jul;64(6–7):761–764.
   PubMedGoogle Scholar
• Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989 Apr 15;49(8):2175–2183.
   PubMed Web of Science ®Google Scholar
• Furlanut M, Franceschi L, Pasqual E, et al. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit. 2007 Jun;29(3):349–352.
   PubMed Web of Science ®Google Scholar
• Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica. 1973 Nov;3(11):711–714.
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062–1075.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Slater SR. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep. 1980 Jun-Jul;64(6–7):741–744.
   PubMedGoogle Scholar
• Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004 May;85(2):151–159.
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 3;95(23):1758–1764.
   PubMed Web of Science ®Google Scholar
• Wu X, Hawse JR, Subramaniam M, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009 Mar 1;69(5):1722–1727.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Xu C, Pei Z, et al. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat. 2012 May;133(1):99–109.
   PubMed Web of Science ®Google Scholar
• Lv W, Liu J, Lu D, et al. Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem. 2013 Jun 13;56(11):4611–4618.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Thorn CF, Desta Z, et al. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013 Nov;23(11):643–647.
   PubMed Web of Science ®Google Scholar
• Brauch H, Murdter TE, Eichelbaum M, et al. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009 Oct;55(10):1770–1782.
   PubMed Web of Science ®Google Scholar
• Murdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011 May;89(5):708–717.
   PubMed Web of Science ®Google Scholar
• Klopp-Schulze L, Mueller-Schoell A, Neven P, et al. Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen. Front Pharmacol. 2020;11:283.
   PubMed Web of Science ®Google Scholar
• van Nuland M, Vreman RA, Ten Ham RMT, et al. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. Breast Cancer Res Treat. 2018 Nov;172(1):143–150.
   PubMed Web of Science ®Google Scholar
• Lenehan JG, Teft WA, Kim RB. Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen. J clin oncol. 2016 May 20;34:15.
   Web of Science ®Google Scholar
• Lien EA, Soiland H, Lundgren S, et al. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat. 2013 Sep;141(2):243–248.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Frenay M, Etienne MC, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther. 1996 Apr;59(4):401–410.
   PubMed Web of Science ®Google Scholar
• Wu AH, Pike MC, Williams LD, et al. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol. 2007 Jul 20;25(21):3024–3030.
   PubMed Web of Science ®Google Scholar
• Antunes MV, Timm TA, de Oliveira V, et al. Influence of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D Status on tamoxifen biotransformation. Ther Drug Monit. 2015 Dec;37(6):733–744.
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Ozdemir NY, et al. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. J BUON. 2016 Jan-Feb;21(1):27–34.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Pritchard KI. Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol. 2010 Jul 20;28(21):3405–3407.
   PubMed Web of Science ®Google Scholar
• Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May;89(5):718–725.
   PubMed Web of Science ®Google Scholar
• Antunes MV, de Oliveira V, Raymundo S, et al. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. Pharmacogenomics. 2015;16(6):601–617.
   PubMed Web of Science ®Google Scholar
• Binkhorst L, Kloth JSL, de Wit AS, et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat. 2015 Jul;152(1):119–128.
   PubMed Web of Science ®Google Scholar
• Teft WA, Gong IY, Dingle B, et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat. 2013 May;139(1):95–105.
   PubMed Web of Science ®Google Scholar
• Binkhorst L, van Gelder T, Loos WJ, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther. 2012 Jul;92(1):62–67.
   PubMed Web of Science ®Google Scholar
• Gryn SE, Teft WA, Kim RB. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. Pharmacogenet Genomics. 2014 Jul;24(7):367–369.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011 Mar 16;103(6):489–500.
   PubMedGoogle Scholar
• Dezentjé VO, Guchelaar HJ, Nortier JW, et al. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res. 2009 Jan 1;15(1):15–21.
   PubMed Web of Science ®Google Scholar
• Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res. 2008 Sep 15;14(18):5913–5918.
   PubMed Web of Science ®Google Scholar
• Aubert RE, Stanek EJ, Yao J, et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J clin oncol. 2009;27(18_suppl):CRA508–CRA508.
   Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Cronin-Fenton DP, et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2562–2564.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010 Feb;8(340):c693.
   Google Scholar
• Thompson AM, Johnson A, Quinlan P, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011 Jan;125(1):279–287.
   PubMed Web of Science ®Google Scholar
• Fotoohi AK, Karim H, Lafolie P, et al. Pronounced interindividual but not intraindividual variation in tamoxifen and metabolite levels in plasma during adjuvant treatment of women with early breast cancer. Ther Drug Monit. 2016 Apr;38(2):239–245.
   PubMed Web of Science ®Google Scholar
• Woo HI, Lee SK, Kim J, et al. Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget. 2017 Nov 21;8(59):100296–100311.
   PubMedGoogle Scholar
• Jager NG, Rosing H, Schellens JH, et al. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat. 2014 Feb;143(3):477–483.
   PubMed Web of Science ®Google Scholar
• Sima M, Vodicka M, Maresova V, et al. Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int J Clin Pharm. 2017 Oct;39(5):1095–1100.
   PubMed Web of Science ®Google Scholar
• Pistilli B, Paci A, Ferreira AR, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020 Jun 22; JCO1901758. DOI:10.1200/JCO.19.01758
   Web of Science ®Google Scholar
• Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res. 2004 Apr 1;10(7):2336–2343.
   PubMed Web of Science ®Google Scholar
• Saladores P, Murdter T, Eccles D, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015 Feb;15(1):84–94.
   PubMed Web of Science ®Google Scholar
• Helland T, Henne N, Bifulco E, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017 Nov 28;19(1):125.
   PubMedGoogle Scholar
• Sanchez-Spitman AB, Moes DAR, Swen JJ, et al. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. Cancer Chemother Pharmacol. 2020 Jun;85(6):1141–1152.
   PubMed Web of Science ®Google Scholar
• Neven P, Jongen L, Lintermans A, et al. Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res. 2018 May 15;24(10):2312–2318.
   PubMed Web of Science ®Google Scholar
• Takano T, Imamura CK, Tamura K, et al. A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1. J clin oncol. 2018;36(15_suppl):1046.
   Web of Science ®Google Scholar
• Love RR, Desta Z, Flockhart D, et al. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. Springerplus. 2013 Dec;2(1):52.
   PubMedGoogle Scholar
• Dezentje VO, Opdam FL, Gelderblom H, et al. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Res Treat. 2015 Oct;153(3):583–590.
   PubMed Web of Science ®Google Scholar
• Klopp-Schulze L, Joerger M, Wicha SG, et al. Exploiting pharmacokinetic models of tamoxifen and endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients. Clin Pharmacokinet. 2018 Feb;57(2):229–242.
   PubMed Web of Science ®Google Scholar
• Fox P, Balleine RL, Lee C, et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE study. Clin Cancer Res. 2016 Jul 1;22(13):3164–3171.
   PubMed Web of Science ®Google Scholar
• Helland T, Hagen KB, Haugstoyl ME, et al. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian prescription database. Breast Cancer Res Treat. 2019 Aug;177(1):185–195.
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5;97(1):30–39.
   PubMed Web of Science ®Google Scholar
• Lim H-S, Lee HJ, Lee KS, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25(25):3837–3845.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287–1293.
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006 Jul;80(1):61–74.
   PubMed Web of Science ®Google Scholar
• Hertz DL, Snavely AC, McLeod HL, et al. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol. 2015 Nov;80(5):1122–1130.
   PubMed Web of Science ®Google Scholar
• Yenny PSS, Purwanto DJ, et al. Association of CYP2D6*10 (c. 100 C>T) genotype with Z-END concentration in patients with breast cancer receiving tamoxifen therapy in Indonesian population. Endocr Metab Immune Disord Drug Targets. 2019;19(8):1198–1206.
   PubMed Web of Science ®Google Scholar
• Ahmed JH, Makonnen E, Fotoohi A, et al. CYP2D6 genotype predicts plasma concentrations of tamoxifen metabolites in ethiopian breast cancer patients. Cancers (Basel). 2019 Sep 12;11(9):1353.
   Web of Science ®Google Scholar
• Nardin JM, Schroth W, Almeida TA, et al. The influences of adherence to tamoxifen and cyp2d6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer. Clin Transl Sci. 2020 Mar;13(2):284–292.
   PubMed Web of Science ®Google Scholar
• Puszkiel A, Arellano C, Vachoux C, et al. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: preliminary Results of the French PHACS Study. Clin Pharmacol Ther. 2019 Sep;106(3):585–595.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wu HW, Zhang YH. Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis. Cancer Chemother Pharmacol. 2019 Jan;83(1):71–79.
   PubMed Web of Science ®Google Scholar
• Hennig EE, Piątkowska M, Goryca K, et al. Non-CYP2D6 variants selected by a GWAS Improve the prediction of impaired tamoxifen metabolism in patients with breast cancer. J Clin Med. 2019 Jul 24; 8: 8.
   Web of Science ®Google Scholar
• Thorén L, Lindh JD, Ackehed G, et al. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. Br J Clin Pharmacol. 2020 Jul; 26. DOI: 10.1111/bcp.14500.
   Google Scholar
• Gusella M, Pasini F, Corso B, et al. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable? Pharmacol Res Perspect. 2020 Oct;8(5):e00646.
   PubMed Web of Science ®Google Scholar
• Khalaj Z, Baratieh Z, Nikpour P, et al. Clinical trial: CYP2D6 related dose escalation of tamoxifen in breast cancer patients with iranian ethnic background resulted in increased concentrations of tamoxifen and its metabolites. Front Pharmacol. 2019;10:530.
   PubMed Web of Science ®Google Scholar
• Tamura K, Imamura CK, Takano T, et al. CYP2D6 genotype–guided tamoxifen dosing in hormone receptor–positive metastatic breast cancer (TARGET-1): a randomized, open-label, phase II study. J Clin Oncol. 2020;38(6):558–566.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20;23(36):9312–9318.
   PubMed Web of Science ®Google Scholar
• Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014 Feb;95(2):216–227.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Sun JX, Suman VJ, et al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 8;107: 2.
   Google Scholar
• Rae JM, Leyland-Jones B, Regan M, et al. Re: loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2015 May;107(5):djv065–djv065.
   PubMedGoogle Scholar
• Goetz MP, Brauch H, Ratain MJ, et al. Re: concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2014 Apr 3;106: 5.
   Google Scholar
• Nowell S, Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene. 2006 Mar 13;25(11):1673–1678.
   PubMed Web of Science ®Google Scholar
• Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 2010;12(4):R64.
   PubMed Web of Science ®Google Scholar
• Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012 Mar 21;104(6):452–460.
   PubMed Web of Science ®Google Scholar
• Sestak I, Kealy R, Nikoloff M, et al. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer. 2012 Jul 10;107(2):230–233.
   PubMed Web of Science ®Google Scholar
• Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012 Mar 21;104(6):441–451.
   PubMed Web of Science ®Google Scholar
• Jorge-Aarón RM, Rodrigo RC, de Jesús AI, et al. CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment. Per Med. 2020 Jul 1;17(4):261–270.
   PubMed Web of Science ®Google Scholar
• Mayer SE, Weiss NS, Chubak J, et al. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019 Jan;30(1):103–112.
   PubMed Web of Science ®Google Scholar
• De Ameida Melo M, De Vasconcelos-Valença RJ, Neto FM, et al. CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence. Biomed Rep. 2016 Nov;5(5):574–578.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan;101(1):113–121.
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187–5193.
   PubMed Web of Science ®Google Scholar
• Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat. 2009 Nov;118(1):125–130.
   PubMed Web of Science ®Google Scholar
• Damodaran SE, Pradhan SC, Umamaheswaran G, et al. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol. 2012 Jul;70(1):75–81.
   PubMed Web of Science ®Google Scholar
• Yazdi MF, Rafieian S, Gholi-Nataj M, et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783–6787.
   PubMedGoogle Scholar
• Lei L, Wang X, Wu XD, et al. Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res. 2016;8(8):3585–3592.
   PubMed Web of Science ®Google Scholar
• Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian tamoxifen trial. J clin oncol. 2006;24(22):3708–3709.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013 Jan 15;19(2):500–507.
   PubMed Web of Science ®Google Scholar
• He W, Grassmann F, Eriksson M, et al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J clin oncol. 2020;38(6):548–557.
   PubMed Web of Science ®Google Scholar
• Dreger NM, Degener S, Roth S, et al. Impact of CYP2D6 polymorphisms on tamoxifen treatment in patients with retroperitoneal fibrosis: a first step towards tailored therapy? Urology. 2020 Mar;137:84–90.
   PubMed Web of Science ®Google Scholar
• Sim S, Lövrot J, Lindh JD, et al. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics. 2018 Aug 1;19(13):1027–1037.
   PubMed Web of Science ®Google Scholar
• Lan B, Ma F, Zhai X, et al. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer. 2018 Jul 1;143(1):184–189.
   PubMed Web of Science ®Google Scholar
• Brooks JD, Comen EA, Reiner AS, et al. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res. 2018 Dec 10;20(1):149.
   PubMedGoogle Scholar
• Sanchez-Spitman A, Dezentjé V, Swen J, et al., Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM Study. J clin oncol. 2019;37(8): 636–646.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Nakamura Y, et al. Tamoxifen metabolism and breast cancer recurrence: a question unanswered by CYPTAM. J Clin Oncol. 2019 Aug 1;37(22):1982–1983.
   PubMed Web of Science ®Google Scholar
• Brauch H, Schroth W, Murdter T, et al. Tamoxifen pharmacogenetics and metabolism: the same is not the same. J Clin Oncol. 2019 Aug 1;37(22):1981–1982.
   PubMed Web of Science ®Google Scholar
• Braal CL, Beijnen JH, Koolen SLW, et al. Relevance of endoxifen concentrations: absence of evidence is not evidence of absence. J Clin Oncol. 2019 Aug 1;37(22):1980–1981.
   PubMed Web of Science ®Google Scholar
• Guchelaar HJ, Sanchez-Spitman A, Dezentje V, et al. Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al.. J Clin Oncol. 2019 Aug 1;37(22): 1984–1985.
   PubMed Web of Science ®Google Scholar
• Mugundu GM, Sallans L, Guo Y, et al. Assessment of the impact of CYP3A polymorphisms on the formation of alpha-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos. 2012 Feb;40(2):389–396.
   PubMed Web of Science ®Google Scholar
• Damkier P, Kjaersgaard A, Barker KA, et al. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: analysis of the international tamoxifen pharmacogenomics consortium dataset. Sci Rep. 2017 Aug 10;7(1):7727.
   PubMedGoogle Scholar
• Moyer AM, Suman VJ, Weinshilboum RM, et al. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics. 2011 Nov;12(11):1535–1543.
   PubMed Web of Science ®Google Scholar
• Blevins-Primeau AS, Sun D, Chen G, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892–1900.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Christensen M, Cronin-Fenton DP, et al. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937–1943.
   PubMed Web of Science ®Google Scholar
• Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005 Jun;91(3):249–258.
   PubMed Web of Science ®Google Scholar
• Sensorn I, Sirachainan E, Chamnanphon M, et al. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013;6:93–98.
   PubMedGoogle Scholar
• Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2008 Jan;19(1):56–61.
   PubMed Web of Science ®Google Scholar
• Liu J, Sieuwerts AM, Look MP, et al. The 29.5 kb APOBEC3B deletion polymorphism is not associated with clinical outcome of breast cancer. PLoS One. 2016;11(8):e0161731.
   PubMed Web of Science ®Google Scholar
• Brentnall AR, Cuzick J, Byers H, et al. Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Res Treat. 2016 Aug;158(3):591–596.
   PubMed Web of Science ®Google Scholar
• Khan BA, Robinson R, Fohner AE, et al. Cytochrome P450 genetic variation associated with tamoxifen biotransformation in American Indian and Alaska native people. Clin Transl Sci. 2018 May;11(3):312–321.
   PubMed Web of Science ®Google Scholar
• Lim JS, Sutiman N, Muerdter TE, et al. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. Br J Clin Pharmacol. 2016 Jun;81(6):1142–1152.
   PubMed Web of Science ®Google Scholar
• Sutiman N, Lim JSL, Muerdter TE, et al. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in Asian breast cancer patients. Clin Pharmacokinet. 2016 Oct;55(10):1239–1250.
   PubMed Web of Science ®Google Scholar
• Sun D, Chen G, Dellinger RW, et al. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 2006;8(4):R50.
   PubMed Web of Science ®Google Scholar
• Romero-Lorca A, Novillo A, Gaibar M, et al. Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients. PLoS One. 2015;10(7):e0132269.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005 May 1;204(3):216–237.
   PubMed Web of Science ®Google Scholar
• Iusuf D, Teunissen SF, Wagenaar E, et al. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther. 2011 Jun;337(3):710–717.
   PubMed Web of Science ®Google Scholar
• Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos. 2011 Mar;39(3):558–562.
   PubMed Web of Science ®Google Scholar
• Powers JL, Buys SS, Fletcher D, et al. Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9, CYP2C19, and ABCB1. J Clin Pharmacol. 2016 Dec;56(12):1570–1581.
   PubMed Web of Science ®Google Scholar
• Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9(1):R7.
   PubMed Web of Science ®Google Scholar
• Lan B, Ma F, Han M, et al. The effect of polymorphism in UGT1A4 on clinical outcomes of adjuvant tamoxifen therapy for patients with breast cancer in China. Clin Breast Cancer. 2019 Apr;19(2):e370–e375.
   PubMed Web of Science ®Google Scholar
• Falany JL, Macrina N, Falany CN. Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Res Treat. 2002 Jul;74(2):167–176.
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee KM, Park SK, et al. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1090–1095.
   PubMed Web of Science ®Google Scholar
• Wegman P, Vainikka L, Stål O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7(3):R284–90.
   PubMed Web of Science ®Google Scholar
• Nowell S, Sweeney C, Winters M, et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst. 2002 Nov 6;94(21):1635–1640.
   PubMedGoogle Scholar
• Sanchez-Spitman AB, Dezentje VO, Swen JJ, et al. Genetic polymorphisms of 3ʹ-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. Breast Cancer Res Treat. 2018 Nov;172(2):401–411.
   PubMed Web of Science ®Google Scholar
• Fernandez-Santander A, Gaibar M, Novillo A, et al. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. PLoS One. 2013;8(7):e70183.
   PubMed Web of Science ®Google Scholar
• Wlcek K, Svoboda M, Thalhammer T, et al. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther. 2008 Sep;7(9):1450–1455.
   PubMed Web of Science ®Google Scholar
• Zhang X, Pu Z, Ge J, et al. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit. 2015 Feb 21;21:563–569.
   PubMed Web of Science ®Google Scholar
• Pu Z, Zhang X, Chen Q, et al. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. Oncol Rep. 2015 May;33(5):2420–2428.
   PubMed Web of Science ®Google Scholar
• Gao CM, Pu Z, He C, et al. Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen. Oncol Rep. 2017 Aug;38(2):1124–1132.
   PubMed Web of Science ®Google Scholar
• Argalacsova S, Slanar O, Bakhouche H, et al. Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients. J BUON. 2017 Sep-Oct;22(5):1217–1226.
   PubMed Web of Science ®Google Scholar
• Teh LK, Mohamed NI, Salleh MZ, et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. Aaps J. 2012 Mar;14(1):52–59.
   PubMed Web of Science ®Google Scholar
• Argalacsova S, Slanar O, Vitek P, et al. Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer. Physiol Res. 2015;64(Suppl 4):S539–47.
   PubMedGoogle Scholar
• Fejerman L, Ahmadiyeh N, Hu D, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014 Oct 20;5:5260.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Gray KP, Abramovitz M, et al. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat. 2015 Dec;154(3):543–555.
   PubMed Web of Science ®Google Scholar
• Kuo SH, Yang SY, You SL, et al. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 2017 Mar 28;8(13):20925–20938.
   PubMedGoogle Scholar
• Babyshkina N, Vtorushin S, Zavyalova M, et al. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clin Exp Med. 2017 Aug;17(3):383–393.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Gray KP, Abramovitz M, et al. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat. 2015 Jun;151(2):373–384.
   PubMed Web of Science ®Google Scholar
• Wang G, Qin S, Zayas J, et al. 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. Breast Cancer Res Treat. 2019 Jun;175(3):567–578.
   PubMed Web of Science ®Google Scholar
• Johansson H, Gray KP, Pagani O, et al. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res. 2016 Nov 8;18(1):110.
   PubMedGoogle Scholar
• Ingle JN, Liu M, Wickerham DL, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov. 2013 Jul;3(7):812–825.
   PubMed Web of Science ®Google Scholar
• Cairns J, Ingle JN, Wickerham LD, et al. SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERalpha-positive breast cancer through regulation of BRCA1. PLoS Genet. 2017 Oct;13(10):e1007031.
   PubMed Web of Science ®Google Scholar
• Qin S, Ingle JN, Liu M, et al. Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Res. 2017 Aug 18;19(1):95.
   PubMedGoogle Scholar
• Hato Y, Kondo N, Yoshimoto N, et al. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. Int J Clin Oncol. 2016 Jun;21(3):539–547.
   PubMed Web of Science ®Google Scholar
• Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline. J clin oncol. 2016;34(10):1134–1150.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Reid JM, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol. 2017 Oct 20;35(30):3391–3400.
   PubMed Web of Science ®Google Scholar